You are here

Intranasal Delivery of MSCs for BPD

Bronchopulmonary dysplasia (BPD) is the most common cause of morbidity and mortality in extremely premature neonates, and, unfortunately, current therapies for BPD are limited. Preclinical studies have shown that mesenchymal stem cell (MSC) treatment can restore alveolar growth, enhance vascular development, and stimulate tissue repair; however, most of these studies administer MSCs via the intravenous/tracheal route. For the first time, researchers from the lab of Alvaro Moreira (University of Texas Health Science Center San Antonio, USA) show that the intranasal delivery of MSCs for BPD is effective in restoring lung alveolar growth and vascular development. Importantly, this new STEM CELLS Translational Medicine article provides evidence that this non-invasive approach may be employed separately or as an adjunct/alternative to other routes.